Literature DB >> 10614095

Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy.

R Eguchi1, H Ide, T Nakamura, K Hayashi, M Ohta, F Okamoto, H Itoh, K Takasaki.   

Abstract

Postoperative complications were investigated in 72 patients who received neoadjuvant therapy with esophagectomy. Preoperative chemotherapy consisted of 5-fluorouracil (700 mg/m2/day, on days 1 to 5), cisplatinum (70 mg/m2/day, on day 1) and leucovorin (20 mg/m2/day, on days 1 to 5). Preoperative chemoradiotherapy consisted of cisplatinum combined chemotherapy and radiotherapy (total dosage of 30-70 Gy). The incidence of postoperative pneumonia (16%) and anastomotic leakage (24%) in the preoperative chemotherapy group was slightly higher than that in the control group (n = 506), and mortality (6.0%) after esophagectomy in the preoperative chemotherapy group was higher than that (2.4%) of the control group. Postoperative morbidity and mortality were observed more frequently in patients who received two cycles of the chemotherapy than those receiving only one cycle. Postoperative complications occurred more frequently in patients suffering high grade toxicities due to the preoperative chemotherapy. The highest preoperative serum creatinine value correlated to that of postoperative period (r = 0.6494). The use of the preoperative chemoradiotherapy with a total exposure dosage of 60 Gy or more significantly increased the postoperative pneumonia rate (67%; p < 0.05) compared to the group receiving 40 Gy or less. The mortality rate (33%) also increased. The second cycle of the preoperative chemotherapy should be cancelled if patients suffer high grade toxicities during or after the first cycle, and the total exposure dosage of the preoperative chemoradiotherapy should be limited to 40 Gy or less.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614095     DOI: 10.1007/bf03218061

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  11 in total

1.  Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus.

Authors:  H Ide; T Nakamura; K Hayashi; R Eguchi; K Tanigawa; M Ota
Journal:  Semin Surg Oncol       Date:  1997 Jul-Aug

2.  Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.

Authors:  S Law; M Fok; S Chow; K M Chu; J Wong
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

Review 3.  [Neoadjuvant chemotherapy and chemoradiotherapy in the treatment of esophageal cancer].

Authors:  N Ando; S Ozawa; H Miki; T Suwa; M Kitajima
Journal:  Gan To Kagaku Ryoho       Date:  1995-11

4.  Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus.

Authors:  G Ganem; B Dubray; Y Raoul; P Colin; E Bardet; J Y Douillard; M J Goudier; C Hennequin; S Walter; P Michel-Langlet; P Martin; D Maron; F Morvan; P Andolenko; J M Extra
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  The role of neoadjuvant therapy in surgically resectable esophageal cancer.

Authors:  S G Swisher; E C Holmes; K K Hunt; J E Doty; M J Zinner; D W McFadden
Journal:  Arch Surg       Date:  1996-08

6.  [Criteria set by the Japan Society for Cancer Therapy for the determination of solid tumor chemotherapy].

Authors: 
Journal:  Nihon Gan Chiryo Gakkai Shi       Date:  1986-06-20

7.  Induction therapy for squamous carcinoma of thoracic esophagus.

Authors:  E Laterza; C Griso; U S Urso; G dè Manzoni; M Malagò; C Oliani; C Cordiano
Journal:  Ann Thorac Surg       Date:  1994-05       Impact factor: 4.330

8.  Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus.

Authors:  A A Forastiere; M B Orringer; C Perez-Tamayo; S G Urba; S Husted; B J Takasugi; M Zahurak
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

9.  Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.

Authors:  S J Hoff; J R Stewart; J L Sawyers; M J Murray; W H Merrill; R B Adkins; D H Johnson
Journal:  Ann Thorac Surg       Date:  1993-08       Impact factor: 4.330

10.  Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990.

Authors:  B Kavanagh; M Anscher; K Leopold; M Deutsch; E Gaydica; R Dodge; K Allen; D Allen; W Staub; G Montana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

View more
  2 in total

1.  Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer.

Authors:  Simon Law; Kam-Ho Wong; Ka-Fai Kwok; Kent-Man Chu; John Wong
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

2.  Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy.

Authors:  Aoife M Ryan; Aine Hearty; Ruth S Prichard; Aileen Cunningham; Suzanne P Rowley; John V Reynolds
Journal:  J Gastrointest Surg       Date:  2007-10       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.